The cost of treatment dropout in depression : a cost-benefit analysis of fluoxetine vs. tricyclics.
In this study, we tried to estimate the economic potential benefit of the use of fluoxetine (PROZACR 20 mg, Lilly) versus tricyclic antidepressants (TCAs) in depression of mild to moderate intensity.
Fluoxetine has demonstrated, in controlled studies, significantly lower rates of side-effects and treatment dropout than TCAs while showing similar efficacy.
Treatment dropout, especially at an early stage of the therapy, can have profound consequences, including excessive lengthening of the depressive episode, symptomatic relapse, increase of repeated days out of work, even suicides or suicide attempts.
We estimated the expected cost of treatment dropout using a Delphi expert panel.
Mots-clés Pascal : Etat dépressif, Trouble humeur, Fluoxétine, Etude comparative, Antidépresseur, Composé tricyclique, Psychotrope, Chimiothérapie, Traitement, Analyse avantage coût, Abandon traitement, Analyse coût, Economie santé, Santé mentale, France, Europe, Homme
Mots-clés Pascal anglais : Depression, Mood disorder, Comparative study, Antidepressant agent, Tricyclic compound, Psychotropic, Chemotherapy, Treatment, Cost benefit analysis, Treatment dropout, Cost analysis, Health economy, Mental health, France, Europe, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0437232
Code Inist : 002B02B02. Création : 199406.